Konaten

Atomoxetine, the active ingredient in Konaten, is a selective norepinephrine reuptake inhibitor (SNRI) presented as an oral formulation for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults.

GNH USA supplies Konaten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atomoxetine is used in the management of attention deficit hyperactivity disorder (ADHD) by modulating norepinephrine pathways.

- Attention deficit hyperactivity disorder (ADHD) in children and adolescents: Improves attention and reduces hyperactivity and impulsivity. - Attention deficit hyperactivity disorder (ADHD) in adults: Helps control core symptoms and improve daily functioning. - ADHD with comorbid anxiety: May alleviate anxiety symptoms associated with ADHD.

Atomoxetine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Decreased appetite: reduced food intake, especially early in therapy. - Dry mouth: sensation of oral dryness. - Insomnia: difficulty falling or staying asleep. - Dizziness: transient light‑headedness. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Suicidal ideation: emergence of thoughts of self‑harm. - Liver injury: signs of hepatitis or elevated liver enzymes. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Increased blood pressure or heart rate: hypertension or tachycardia. - Psychosis or mania: emergence of severe psychiatric symptoms. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating Atomoxetine, several safety considerations should be addressed.

- Cardiovascular assessment: evaluate blood pressure and heart rate. - Psychiatric monitoring: watch for mood changes, suicidal thoughts, or aggression. - Glaucoma caution: avoid in patients with narrow‑angle glaucoma. - MAOI interaction: do not co‑administer with monoamine oxidase inhibitors within 14 days. - Discontinuation: taper under medical supervision to avoid withdrawal effects. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Atomoxetine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase atomoxetine plasma levels. - Other norepinephrine reuptake inhibitors: additive sympathomimetic effects.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may reduce blood‑pressure control. - Central nervous system stimulants: may increase side‑effect burden such as insomnia or anxiety.